Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pelzer, Uwe ^a   Hilbig, Andreas ^a,b   Stieler, Jens M ^a   Bahra, Marcus ^a   Sinn, Marianne ^a   Gebauer, Bernhard ^a   Dörken, Bernd ^a   Riess, Hanno ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Marien Hospital Hamm   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FEVER; HUMAN; INJECTION SITE IRRITATION; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OUTPATIENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

AGED; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; ENOXAPARIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 84899096955     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-204     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, u. a. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413. u. a.
3. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, u. a. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2003, 21(17):3296-3302. 10.1200/JCO.2003.02.098, 12947065, u. a.
4. Arshad A, Al-Leswas D, Al-Taan O, Stephenson J, Metcalfe M, Steward WP, u. a. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Am J Clin Oncol 2013, 36(4):411-414. 10.1097/COC.0b013e3182124216, 21436672, u. a.
5. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. März 2010, 7(3):163-172.
6. Pelzer U. First-line chemotherapy in advanced pancreatic cancer. Recent Results Cancer Res 2008, 177:57-60. 10.1007/978-3-540-71279-4_7, 18084947.
7. Heinemann V, Philip PA, Pelzer U. Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointest Cancer Res 2009, 3(5 Supplement 2):S43-S47. 2791391, 20011564.
8. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, u. a. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27(33):5513-5518. 10.1200/JCO.2009.24.2446, 19858379, u. a.
9. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, u. a. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825. 10.1056/NEJMoa1011923, 21561347, u. a.
10. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8:82. 10.1186/1471-2407-8-82, 2292732, 18373843.
11. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011, 106(2):371-378. 10.1160/TH10-12-0789, 21713322.
12. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343(25):1846-1850. 10.1056/NEJM200012213432504, 11117976.
13. Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 2009, 20(10):1619-1630. 10.1093/annonc/mdp068, 19561038.
14. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, u. a. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005, 23((10):2123-2129. u. a.
15. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008, 6(4):601-608. 10.1111/j.1538-7836.2008.02908.x, 18208538.
16. Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, u. a Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007, 95((6):507-512. u. a.
17. Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, u. a. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008, 8:361. 10.1186/1471-2407-8-361, 2613915, 19055847, u. a.
18. Oettle H, Arnold D, Kern M, Hoepffner N, Settmacher U, Neuhaus P, u. a. Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. Anticancer Drugs 2002, 13(8):833-838. 10.1097/00001813-200209000-00008, 12394268, u. a.
19. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. Juni 2010, 125(6):490-493.
20. Kleber F-X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003, 145(4):614-621. 10.1067/mhj.2003.189, 12679756.
21. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000, 86(12B):48M-52M.
22. Turpie AGG, Norris TM. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Thromb Haemost. Juli 2004, 92(1):3-12.
23. Zacharski LR, Henderson WG, Forman WB, Edwards RL, Cornell CJ, Forcier RJ, u.a. Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985, 16(5-6):535-561. u.a.
24. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, u. a Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966. 10.1200/JCO.2006.07.9525, 17452677, u. a.